Span Divergent Ltd

Span Divergent Limited was initially incorporated as Span Diagnostics Private Limited on March 31, 1980 as a private limited Company. The Company was converted into a Public Limited Company and the name was changed to Span Diagnostics Limited on August 14, 1993. Thereafter, it attained the name to Span Divergent Limited in 2015. Initially, the Company manufactured a wide range of microbiological, immunological and bio-chemical diagnostic reagents, plastic accessories and allied products at the Udhna Plant. The Company completed expansion-cum-modernisation and mechanisation of packing activities at Udhna. Acquiring three plots of land at GIDC Sachin admeasuring 33,897 sq. mtrs. which is situated near the State Highway and National Highway No.8.This project was finance by way of internal accruals of Rs.31.62 lakhs and balance from Term Loans of Rs.30 lakhs. The Company entered into the technical arrangement with Bioprobe Netherland, Path U.S.A. Dynajen U.S.A. for manufacturing HIV Dipsticks, Myco-dot, Monoclonal anitbodies. Company launched several new products developed by its R & D Center such as One Step Lateral Chromotography Based Assay for monitoring of pregnancy and Hepatitis to be marketed under the brand name of CRYSTAL as well as HIV Flow Through. The continuation distributorship arrangements with Murex Biotech UK Ltd which is now subsidiary of Abbott Diagnostics USA will also generate substantial business from the nitche market of the Blood Bank Segment. During the year 2007-08, the Company renovated its production and administrative facilities. It acquired technology from France for production of Monoclonal Antibodies. A joint venture company in the name of Span Diagnostics SARL was formed in Nov'05, in the city of Compiegne, France. A joint venture company between Nihon Kohden Corporation, Japan and Span Diagnostics Ltd., India, started its operation from December 2008 and started manufacturing high quality reagents for Hematology Analysers for distribution and sale in India under license agreement with Nihon Kohden Corporation, Japan. The Company formed joint venture Company during year 2011-12 with Reindus Health (Pty) Limited. During the year 2013 -14, Span Biotherapeutics Pvt. Ltd., subsidiary Company ceased to be a subsidiary Company with effect from May 27, 2013. In 2014-15, the Company transferred its 95.24% stake held in subsidiary Span Biotronics Private Limited to M/s. Arkray Helathcare Private Limited and ceased to be a subsidiary Company with effect from March 05, 2015. The Company acquired 540 Equity Shares of Rand 1 Each from its existing shareholders of the Company. Upon acquisition of 540 Equity Shares of, Span Diagnostics South Africa (Pty) Limited, it became wholly owned overseas subsidiary Company. During FY 2015-16, Company sold its investment in Span Nihon Kohden Diagnostics Private Limited which resulted into exceptional income. Subsequent to sale of investment held in Span Nihon Kohden Diagnostics Private Limited, Company's joint venture with the said Company came to an end. Similarly, the Company had sold its In-Vitro Diagnostics (IVD) Business to Japanese affiliated Company, M/S. Arkray Healthcare Private Limited through Slump Sale effective from March 05, 2015 and invested in different businesses through various subsidiaries. During year 2015-16, Company incorporated new LLPs as under to carry out new businesses in FAB and HCLS verticals in respective entities comprising of Dryfruit Factory LLP; Span Diagnostics Products LLP; Biospan Scientific LLP and Aranya Agri Biotech LLP. M/s. BioSpan Contamination Control Solutions Private Limited became joint venture subsidiary Company effective on September 18, 2017. In 2019-20, Company ventured into the diversified business in Food processing, Life science and Agri biotech. From 2022 onwards, it formed a separate division 'Spanyan Business Assistance' to focus on providing CXO services. The Company has sold its In-Vitro Diagnostics Business Undertaking on March 05, 2015 and has invested in different businesses through various subsidiaries.